A hypergolic metal organic framework material for producing a hypergol when combined with an oxidizer, comprising a general structure M1-L-M2, wherein L is an aromatic organic linker comprising one or more unsaturated substituents, and wherein M1 and M2 are same or different metal cations.

Metal-organic frameworks (MOFs) comprising amines on the organic linker can be used for cell targeting. In particular, primary amine groups represent one of the most versatile chemical moieties for conjugation to biologically relevant molecules, including antibodies and enzymes. Different chemical conjugation schemes can be used to conjugate biological molecules to the amino functionality on the organic linker. For example, carbodiimide chemistry can be used to link a primary amine to available carboxyl groups on the protein. For example, sulfhydryl crosslinking chemistry can be used via Traut's reagent scheme. As a demonstration of the invention, the ability of EpCAM antibody-targeted MOFs to bind to a human epithelial cell line (A549), a common target for imaging studies, was confirmed with confocal microscopy.

The present invention relates to a plurality of host materials and an organic electroluminescent device comprising the same. By comprising a specific combination of a plurality of host compounds, the organic electroluminescent device according to the present invention provides high efficiency and a long lifespan.

Methods and systems are provided for continuous-flow production of radioisotopes with high specific activity. Radioisotopes with high specific activity produced according to the methods described are also provided. The methods can include causing a liquid capture matrix to contact a target containing a target nuclide; irradiating the target with radiation, ionizing radiation, particles, or a combination thereof to produce the radionuclides that are ejected from the target and into the capture matrix; and causing the liquid capture matrix containing the radionuclides to flow from the target to recover the capture matrix containing the radionuclides with high specific activity. The methods are suitable for the production of a variety of radionuclides. For example, in some aspects the target nuclide is .sup.237Np, and the radionuclide is .sup.238Np that decays to produce .sup.238Pu. In other aspects, the target nuclide is .sup.98Mo, and the radionuclide is .sup.99Mo that decays to produce .sup.99mTc.

Methods and systems are provided for continuous-flow production of radioisotopes with high specific activity. Radioisotopes with high specific activity produced according to the methods described are also provided. The methods can include causing a liquid capture matrix to contact a target containing a target nuclide; irradiating the target with radiation, ionizing radiation, particles, or a combination thereof to produce the radionuclides that are ejected from the target and into the capture matrix; and causing the liquid capture matrix containing the radionuclides to flow from the target to recover the capture matrix containing the radionuclides with high specific activity. The methods are suitable for the production of a variety of radionuclides. For example, in some aspects the target nuclide is .sup.237Np, and the radionuclide is .sup.238Np that decays to produce .sup.238Pu. In other aspects, the target nuclide is .sup.98Mo, and the radionuclide is .sup.99Mo that decays to produce .sup.99mTc.

Disclosed herein is a novel strontium precursor containing a beta-diketonate compound. Being superior in thermal stability and volatility, the strontium precursor can form a quality strontium thin film.

Disclosed herein is a novel strontium precursor containing a beta-diketonate compound. Being superior in thermal stability and volatility, the strontium precursor can form a quality strontium thin film.

The invention relates to the development of drugs intended for the prophylaxis and/or treatment of viral diseases caused, in particular, by herpes viruses. What are proposed are complex compounds of germanium having the general structural formula:
Ge.sub.x[AD][CA].sub.y[AA].sub.2   (1), where AD is a derivative of a nitrogenous base of the purine series that has antiviral activity and can be selected from guanine derivatives, such as acyclovir, valacyclovir, gancyclovir and pencyclovir, or from adenine derivatives, such as vidarabine; CA is a hydroxycarboxylic acid which can be selected from acids such as (but not limited to) citric acid, lactic acid and malic acid; AA is an amino acid which can be selected from various a-amino acids, such as arginine, gylcine, lysine and threonine, and where x=1-2, y=2-4 and z=0-2. Complex compounds of germanium have a high level of antiviral and immune-stimulating activity and are readily soluble in water. The above mentioned compounds are produced by producing an aqueous suspension of germanium dioxide, adding a hydroxycarboxylic acid, a derivative of a nitrogenous base of the purine series and, optionally, but preferably, an amino acid thereto, heating the mixture produced at a temperature of 40-100° C. for 3-14 hours while stirring and removing the water from the solution, thus producing a complex compound of germanium.

A bridged alkaline earth metal alkylphenate having reduced monomeric alkylphenol is prepared by reacting (a) a 4-alkylphenol, unsubstituted at the ortho positions, (b) an alkaline earth metal oxide or hydroxide, (c) a bridging agent comprising sulfur or a carbonyl compound of 1 to about 6, or to 4 or to 2, carbon atoms, and (d) a 2,6-dialkylphenol. The amount of the 2,6-dialkylphenol is 0.05 to 3 moles per 1 mole of the 4-alkylphenol; if there is a molar excess of the 2,6-dialkylphenol, then the excess is added after initial reaction.

The invention relates to metal complex compounds of the formula M.sub.k(L).sub.x(Y).sub.kz-nx, where the ligand L has the formula (I), and to metal complex compounds which include the reaction product of at least one salt or a complex of a transition metal or a main group metal element of the groups 13 to 15 and at least one 1,3-ketoamide. Such complex compounds are suitable in particular as catalysts for polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such metal complex compound as the catalyst. The invention additionally relates to different uses of the two-component polyurethane compositions.